抗CD117抗体在异种移植小鼠中清除正常及骨髓增生异常综合征人类造血干细胞
本研究在体外和异种移植小鼠模型中证实,抗人CD117单克隆抗体SR-1及临床级人源化抗体AMG 191可清除正常及骨髓增生异常综合征(MDS)造血干细胞,并促进正常供者造血干细胞植入,恢复正常人类造血并清除侵袭性病理MDS细胞。
要点
- 抗人CD117单抗SR-1在体外抑制正常脐血和骨髓造血干细胞。
- SR-1与AMG 191在异种移植小鼠体内清除正常及MDS造血干细胞。
- 抗CD117单抗促进正常供者造血干细胞植入MDS异种移植模型并恢复正常造血。
核心结论
- 抗人CD117单克隆抗体有潜力作为新型治疗手段清除MDS造血干细胞并增强异基因造血细胞移植的治愈效果。
- 该研究为将这些抗体药物不仅用于MDS、也用于其他可通过移植改变病情的造血干细胞驱动的血液和免疫疾病奠定了基础。
研究设计与样本
- 研究在体外及异种移植小鼠模型中评估抗人CD117单克隆抗体SR-1和临床级人源化抗人CD117单克隆抗体AMG 191对正常及MDS人造血干细胞的作用。
主要发现
- 抗人CD117单抗SR-1在体外抑制正常脐血和骨髓造血干细胞。
- SR-1和AMG 191在异种移植小鼠模型中体内清除正常及MDS造血干细胞。
- 抗CD117单抗促进正常供者人造血干细胞在MDS异种移植小鼠模型中植入,恢复正常人类造血并清除侵袭性病理MDS细胞。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The myelodysplastic syndromes (MDS) represent a group of clonal disorders that result in ineffective hematopoiesis and are associated with an increased risk of transformation into acute leukemia. MDS arises from hematopoietic stem cells (HSCs); therefore, successful elimination of MDS HSCs is an important part of any curative therapy. However, current treatment options, including allogeneic hematopoietic cell transplantation (HCT), often fail to ablate disease-initiating MDS HSCs, and thus have low curative potential and high relapse rates. Here, we demonstrate that human HSCs can be targeted and eliminated by monoclonal antibodies (mAbs) that bind cell-surface CD117 (c-Kit). We show that an anti-human CD117 mAb, SR-1, inhibits normal cord blood and bone marrow HSCs in vitro. Furthermore, SR-1 and clinical-grade humanized anti-human CD117 mAb, AMG 191, deplete normal and MDS HSCs in vivo in xenograft mouse models. Anti-CD117 mAbs also facilitate the engraftment of normal donor human HSCs in MDS xenograft mouse models, restoring normal human hematopoiesis and eradicating aggressive pathologic MDS cells. This study is the first to demonstrate that anti-human CD117 mAbs have potential as novel therapeutics to eradicate MDS HSCs and augment the curative effect of allogeneic HCT for this disease. Moreover, we establish the foundation for use of these antibody agents not only in the treatment of MDS but also for the multitude of other HSC-driven blood and immune disorders for which transplant can be disease-altering.
引用
- Pang WW, Czechowicz A, Logan AC, et al. Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice. Blood. 2019. PMID: 30745302. doi:10.1182/blood-2018-06-858159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。